TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intraoperative remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of S-ECC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mobility as measured with the four-item Barthel index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pain as measured using the visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of progression to AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median time to BAP progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy scores for the International Index of Erectile Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDITS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of pelvic fluid collections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference between lead tips
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average radial error between lead tips
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average depth error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GADA levels at 15 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in fasting and stimulated C-peptide at 15 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TXB2 inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of paresis SC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average time of pain alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥1-stage fibrosis improvement and no worsening of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: mean reduction in lower and lateral periorbital wrinkle score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fluorescence intensity of CD25 expression in resting T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of IL‐10 to IL‐12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microalbuminuria prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorespiratory fitness (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic/diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total number of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Acute grade ≥2 gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative worst late gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL) domain scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Repigmentation >50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Repigmentation >75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to achieve primary end point
Endpoint domain: Mortality/survival
Primary endpoint: microleakage at the cervical dentin margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of low SVC flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean lowest superior vena cava (SVC) flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: right ventricular output (RVO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical benefits (CR, PR, stable disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Wetted areas of hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment optimization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Informed consent improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery of spontaneous breathing and consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all-cause rehospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful treatment at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure to remove polyps
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with pronunciation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with esthetic effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RRV-specific IgG titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lowest PaO2 value during one-lung anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of chest symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: soreness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective satiety response (AUC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with cosmetic result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for same treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean reduction in asthma and rhinitis symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade III and IV hematotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Grade III and IV renal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Objective partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Intervention Anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anticipation of pain scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean office visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: denture satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fibrinogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ItchyQol score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Family attitude towards mental illness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fat intake reduction of ≥ 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Cerebral blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG theta and beta 2 power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective measures of fatigue and energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Long-term success defined as no use of benzodiazepines during follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Ulcer recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: True positive rate at cutoff levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vegetable consumption (bell peppers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for eating the vegetable again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reactive oxygen species (ROS) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inter‐Cellular Adhesion Molecule‐1 (ICAM‐1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apoptosis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean time to expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admissions with anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of high parasite density malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Protective efficacy against all episodes of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of safety practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discharge criteria attainment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hospital admission rates
Endpoint domain: Adverse events/effects
Primary endpoint: Predicted uptake of HIV testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Warmth detection threshold (WDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat pain threshold (HPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of supra threshold heat pain (STHP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative use of opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum bupivacaine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity of the virtual simulator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oxybutynin AUC(24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxybutynin AUC(48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Surface Area (BSA) involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPRINT performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negativity of HBV DNA (<1.6 pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of HBeAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of HBeAg/anti-HBe seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose (BG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean insulin doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of human epididymis protein 4 in ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mandibular length increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability of class II malocclusion correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Attachment Level (CAL)
Endpoint domain: Physiological/clinical
Primary endpoint: net cost saving per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost per success
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: death prevented
Endpoint domain: Mortality/survival
Primary endpoint: WOMAC and pain scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: INH Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained release dissolution profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of absorption (Cmax and Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission off steroids at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean DAI scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in screening intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of preterm labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Neonatal morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIPN scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: chronic post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for Veda-scope over bivalve speculum
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comfort level during Pap smear collection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LDL-cholesterol-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: risk of recurrent seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neointimal hyperplasia (NIH) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage luminal volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: EPR clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPR total number of inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LPR clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of resulting passive fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Participant retention to study completion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Postoperative VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of bowel movement and walking ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to total crusting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to uninterrupted sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Accuracy of MDMs in detecting HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Executive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion recognition skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rates at month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for booster dose due to anti-HBs loss
Endpoint domain: Adverse events/effects
Primary endpoint: lower extremity strength improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in tandem gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in physical and overall disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fatigue VAS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: occurrence of PPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin difference before and after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT‐General Total score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FACT‐An Fatigue subscale score change
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: FACT‐An Anemia subscale score change
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: HIV‐1 DNA level in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Viability of prophase I oocytes post-thaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maturation rate to metaphase II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of abortion within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time from mifepristone to uterine expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median misoprostol dosing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma IL-25 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux associated with venous symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Visualization of sentinel lymph nodes (SLN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of nasolabial folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum effect (E(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach maximum plasma concentration (t(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse symptom scores improvement
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse symptom scores worsening
Endpoint domain: Adverse events/effects
Primary endpoint: insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: total CO2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knee Society knee scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aseptic loosening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: wrong‐patient order sessions per 100000
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistent compensatory behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early vascular surgical site infection incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Readmissions related to surgical site infections
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of Gram-positive related infections
Endpoint domain: Adverse events/effects
Primary endpoint: CCTDI scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Retinal vessel tortuosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of the ITA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free-flow capacity of the ITA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for rescue antiemetic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bulbar conjunctival redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes